Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -445.21 Billion JPY | -113.99% |
| 2022 | -208.06 Billion JPY | 17.34% |
| 2021 | -251.71 Billion JPY | -25.2% |
| 2020 | -201.04 Billion JPY | -5.16% |
| 2019 | -191.18 Billion JPY | -30.38% |
| 2018 | -146.64 Billion JPY | -5.7% |
| 2017 | -138.73 Billion JPY | -46.47% |
| 2016 | -94.72 Billion JPY | 6.19% |
| 2015 | -100.97 Billion JPY | 11.29% |
| 2014 | -113.82 Billion JPY | 0.88% |
| 2013 | -114.83 Billion JPY | -3.52% |
| 2012 | -110.93 Billion JPY | -3.52% |
| 2011 | -107.16 Billion JPY | -40.61% |
| 2010 | -76.21 Billion JPY | 28.76% |
| 2009 | -106.97 Billion JPY | -51.18% |
| 2008 | -70.76 Billion JPY | 3.23% |
| 2007 | -73.12 Billion JPY | -7.25% |
| 2006 | -68.18 Billion JPY | 8.33% |
| 2005 | -74.38 Billion JPY | -31.93% |
| 2004 | -56.38 Billion JPY | -60.1% |
| 2003 | -35.21 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -387.17 Billion JPY | 13.65% |
| 2024 Q1 | -456.01 Billion JPY | -2.42% |
| 2023 Q1 | -239.52 Billion JPY | -15.12% |
| 2023 Q3 | -322.9 Billion JPY | 9.66% |
| 2023 Q2 | -357.42 Billion JPY | -49.22% |
| 2023 FY | -445.21 Billion JPY | -113.99% |
| 2023 Q4 | -445.21 Billion JPY | -37.88% |
| 2022 Q3 | -264.67 Billion JPY | 24.61% |
| 2022 Q4 | -208.06 Billion JPY | 21.39% |
| 2022 Q2 | -351.06 Billion JPY | -59.3% |
| 2022 Q1 | -220.38 Billion JPY | 12.45% |
| 2022 FY | -208.06 Billion JPY | 17.34% |
| 2021 FY | -251.71 Billion JPY | -25.2% |
| 2021 Q1 | -162.04 Billion JPY | 21.98% |
| 2021 Q2 | -182.39 Billion JPY | -12.56% |
| 2021 Q3 | -187.52 Billion JPY | -2.81% |
| 2021 Q4 | -251.71 Billion JPY | -34.23% |
| 2020 Q2 | -196.6 Billion JPY | -41.74% |
| 2020 Q1 | -138.71 Billion JPY | 30.1% |
| 2020 Q3 | -182.71 Billion JPY | 7.07% |
| 2020 FY | -201.04 Billion JPY | -5.16% |
| 2020 Q4 | -207.69 Billion JPY | -13.68% |
| 2019 Q1 | -125.81 Billion JPY | 14.2% |
| 2019 FY | -191.18 Billion JPY | -30.38% |
| 2019 Q2 | -149.16 Billion JPY | -18.56% |
| 2019 Q4 | -198.45 Billion JPY | -12.11% |
| 2019 Q3 | -177.02 Billion JPY | -18.68% |
| 2018 Q3 | -145.73 Billion JPY | 5.57% |
| 2018 Q4 | -146.64 Billion JPY | -0.63% |
| 2018 Q1 | -152.5 Billion JPY | -9.92% |
| 2018 FY | -146.64 Billion JPY | -5.7% |
| 2018 Q2 | -154.31 Billion JPY | -1.19% |
| 2017 Q4 | -138.73 Billion JPY | -42.72% |
| 2017 Q2 | -110.29 Billion JPY | -7.03% |
| 2017 Q1 | -103.04 Billion JPY | -8.79% |
| 2017 FY | -138.73 Billion JPY | -46.47% |
| 2017 Q3 | -97.21 Billion JPY | 11.86% |
| 2016 Q4 | -94.72 Billion JPY | 4.7% |
| 2016 FY | -94.72 Billion JPY | 6.19% |
| 2016 Q1 | -106.07 Billion JPY | -5.05% |
| 2016 Q3 | -99.39 Billion JPY | 0.03% |
| 2016 Q2 | -99.42 Billion JPY | 6.27% |
| 2015 Q4 | -100.97 Billion JPY | 16.41% |
| 2015 Q3 | -120.79 Billion JPY | 4.44% |
| 2015 Q2 | -126.4 Billion JPY | -2.43% |
| 2015 FY | -100.97 Billion JPY | 11.29% |
| 2015 Q1 | -123.41 Billion JPY | -8.43% |
| 2014 FY | -113.82 Billion JPY | 0.88% |
| 2014 Q1 | -114.78 Billion JPY | 0.04% |
| 2014 Q4 | -113.82 Billion JPY | -5.47% |
| 2014 Q3 | -107.92 Billion JPY | 16.05% |
| 2014 Q2 | -128.54 Billion JPY | -11.99% |
| 2013 Q3 | -112.11 Billion JPY | -11.88% |
| 2013 Q4 | -114.83 Billion JPY | -2.43% |
| 2013 Q2 | -100.2 Billion JPY | 0.09% |
| 2013 FY | -114.83 Billion JPY | -3.52% |
| 2013 Q1 | -100.29 Billion JPY | 9.38% |
| 2012 FY | -110.93 Billion JPY | -3.52% |
| 2012 Q1 | -123.1 Billion JPY | -15.08% |
| 2012 Q2 | -129.97 Billion JPY | -5.58% |
| 2012 Q3 | -97.11 Billion JPY | 25.28% |
| 2012 Q4 | -110.67 Billion JPY | -13.96% |
| 2011 FY | -107.16 Billion JPY | -40.61% |
| 2011 Q4 | -106.97 Billion JPY | 3.34% |
| 2011 Q2 | -109.22 Billion JPY | -7.38% |
| 2011 Q1 | -101.71 Billion JPY | -33.47% |
| 2011 Q3 | -110.67 Billion JPY | -1.32% |
| 2010 Q3 | -70.17 Billion JPY | 13.65% |
| 2010 Q4 | -76.21 Billion JPY | -8.6% |
| 2010 FY | -76.21 Billion JPY | 28.76% |
| 2010 Q2 | -81.27 Billion JPY | 19.64% |
| 2010 Q1 | -101.13 Billion JPY | 5.46% |
| 2009 Q4 | -106.97 Billion JPY | -37.82% |
| 2009 Q3 | -77.62 Billion JPY | 14.54% |
| 2009 Q2 | -90.83 Billion JPY | -17.08% |
| 2009 Q1 | -77.58 Billion JPY | 0.0% |
| 2009 FY | -106.97 Billion JPY | -51.18% |
| 2008 FY | -70.76 Billion JPY | 3.23% |
| 2007 FY | -73.12 Billion JPY | -7.25% |
| 2006 FY | -68.18 Billion JPY | 8.33% |
| 2005 FY | -74.38 Billion JPY | -31.93% |
| 2004 FY | -56.38 Billion JPY | -60.1% |
| 2003 FY | -35.21 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 2057.021% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 1584.063% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | -27830.22% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 2808343.976% |
| Novartis AG | 12.95 Billion USD | 3536.658% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -262254.078% |